Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 41 Show results per page	View Search Criteria \| Help With Results


1.		Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				CAM307 NCT00046683


2.		Fludara Plus Alemtuzumab (Campath, MabCampath) vs Fludara Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				CAM314 NCT00086580

Last Modified: 12/14/2007 First Published: 5/23/2003


3.		Phase I/II Study of Alemtuzumab During Post-Remission Intensification Therapy in Patients With Untreated Acute Lymphoblastic Leukemia (Phase I portion closed to accrual as of 7/5/2005)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				15 and over				NCI				CALGB-10102 NCT00061945


4.		Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				0 to 70				Other				H8714 DIMSUM, NCT00048412

Last Modified: 12/12/2007 First Published: 5/28/2004


5.		Phase I/II Pilot Study of a Reduced-Intensity Conditioning Regimen Comprising Alemtuzumab, Fludarabine, and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total Body Radiotherapy Followed By Haplotype-Mismatched, KIR Class I Epitope-Mismatched CD34-Positive Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Relapsed, Refractory, or Poor-Risk Hematological Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 to 60				NCI				CALGB-100102 NCT00085449

Last Modified: 12/10/2008 First Published: 1/20/2006


6.		Phase I/II Pilot Study of Induction Therapy Comprising Fludarabine and Cyclophosphamide Followed By Allogeneic Stem Cell Transplantation in Patients With High-Risk B-Cell Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 to 65				Other, Pharmaceutical / Industry				GCLLSG-CLL3X EU-20554, MEDAC-FLUD.10/CLL, NCT00281983

Last Modified: 5/22/2007 First Published: 12/1/1999


7.		Phase II Study of Allogeneic Mixed Chimerism Peripheral Blood Stem Cell Transplantation Utilizing In Vivo and In Vitro Alemtuzumab (Monoclonal Antibody CD52; Campath-1H) in Patients With High-Risk Hematologic Malignancies or Refractory Breast or Renal Cell Cancer or Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				DUMC-1340-99-7 NCI-G99-1617, NCT00004143

Last Modified: 12/5/2007 First Published: 3/1/2000


8.		Phase II Study of Fludarabine Induction Followed By Alemtuzumab Consolidation in Previously Untreated Patients With Stage I, II, III, or IV B-Cell Chronic Lymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				CLB-19901 NCT00004857, CALGB-19901

Last Modified: 3/30/2005 First Published: 10/1/2000


9.		Phase II Study of Alemtuzumab (Monoclonal Antibody CD52; Campath-1H) and Peripheral Blood Stem Cell Transplantation in Patients With Chronic Lymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 to 65				NCI				ECOG-8998 E8998, NCT00006390

Last Modified: 8/1/2007 First Published: 12/1/2001


10.		Phase II Study of a Nonmyeloablative Regimen Comprising Melphalan, Fludarabine, and Alemtuzumab Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Lymphohematopoietic Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				70 and under				NCI				MSKCC-01092 NCI-G01-2028, NCT00027560

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute